Literature DB >> 27550342

Stage-Specific Embryonic Antigen-1 (SSEA-1) Expression in Thyroid Tissues.

Jin Xu1, Heather Hardin1, Ranran Zhang1, Kaitlin Sundling1, Darya Buehler1, Ricardo V Lloyd2.   

Abstract

Stage-specific embryonic antigen-1 (SSEA-1), also known as CD15, is a member of a cluster of differentiation antigens that have been identified in various normal tissues and in different types of cancers including papillary and medullary thyroid carcinoma. SSEA-1 may be expressed in normal stem cells and cancer stem-like cells. To evaluate the potential diagnostic and prognostic utility of SSEA-1 in thyroid tumors, we analyzed the expression of SSEA-1 in normal and neoplastic thyroid tissues by immunohistochemistry (IHC) using a tissue microarray with 158 different tissue cores. To evaluate the potential utility of SSEA-1 as a surface marker, we also assessed the expression of SSEA-1 in thyroid cell lines by flow cytometric analysis. SSEA-1 immunoreactivity was identified in malignant thyroid follicular epithelial cancers but not in the benign thyroid tissues. Anaplastic thyroid (ATC) (80 %) and conventional papillary thyroid carcinoma (PTC) (60.7 %) showed significantly higher percentage of cases that were SSEA-1 immunoreactive than follicular variant of papillary thyroid carcinoma (FVPTC) (20.6 %) and follicular carcinoma (FCA) (32.1 %). Flow cytometric analysis of cultured thyroid cell lines showed that a small subpopulation of ATC and PTC thyroid tumor cells had SSEA-1 immunoreactivity which may represent thyroid cancer stem-like cells. The ATC cells expressed more SSEA-1 immunoreactive cells than the PTC cell lines. Our findings suggest that expression of SSEA-1 immunoreactivity in thyroid neoplasms was associated with more aggressive thyroid carcinomas. SSEA-1 is a marker that detects malignant thyroid neoplasms in formalin-fixed paraffin-embedded thyroid tissue sections and may be a useful marker for thyroid cancer stem-like cells.

Entities:  

Keywords:  CD15; Flow cytometry; SSEA-1; Thyroid carcinoma

Mesh:

Substances:

Year:  2016        PMID: 27550342      PMCID: PMC5107349          DOI: 10.1007/s12022-016-9448-1

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  28 in total

1.  Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells.

Authors:  Michael F Clarke; John E Dick; Peter B Dirks; Connie J Eaves; Catriona H M Jamieson; D Leanne Jones; Jane Visvader; Irving L Weissman; Geoffrey M Wahl
Journal:  Cancer Res       Date:  2006-09-21       Impact factor: 12.701

2.  Immunocytochemical evaluation of HBME-1, CA 19-9, and CD-15 (Leu-M1) in fine-needle aspirates of thyroid nodules.

Authors:  K H van Hoeven; A J Kovatich; M Miettinen
Journal:  Diagn Cytopathol       Date:  1998-02       Impact factor: 1.582

3.  A monoclonal antibody (MMA) that identifies a differentiation antigen on human myelomonocytic cells.

Authors:  S N Hanjan; J F Kearney; M D Cooper
Journal:  Clin Immunol Immunopathol       Date:  1982-05

4.  Expression of epithelial-mesenchymal transition regulators SNAI2 and TWIST1 in thyroid carcinomas.

Authors:  Darya Buehler; Heather Hardin; Weihua Shan; Celina Montemayor-Garcia; Patrick S Rush; Sofia Asioli; Herbert Chen; Ricardo V Lloyd
Journal:  Mod Pathol       Date:  2012-08-17       Impact factor: 7.842

5.  Evaluation of expression of CD15 and sCD15 in non-small cell lung cancer.

Authors:  A Kadota; M Masutani; M Takei; T Horie
Journal:  Int J Oncol       Date:  1999-12       Impact factor: 5.650

6.  HBME-1 and CD15 immunocytochemistry in the follicular variant of thyroid papillary carcinoma.

Authors:  Makoto Ohta; Tadakazu Ookoshi; Hironobu Naiki; Yoshiaki Imamura
Journal:  Pathol Int       Date:  2015-01-19       Impact factor: 2.534

7.  Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumours. Preferential reactivity with malignant tumours.

Authors:  M Miettinen; P Kärkkäinen
Journal:  Virchows Arch       Date:  1996-11       Impact factor: 4.064

8.  CD15 (LeuM1) immunoreactivity: prognostic factor for sporadic and hereditary medullary thyroid cancer? Study Group on Multiple Endocrine Neoplasia of Austria.

Authors:  F Längle; T Soliman; N Neuhold; G Widhalm; B Niederle; S Roka; K Kaserer; W Blauensteiner; K Dam; M Clodi
Journal:  World J Surg       Date:  1994 Jul-Aug       Impact factor: 3.352

9.  Expression of the CD15 antigen (Lewis x) in breast cancer.

Authors:  S A Brooks; A J Leathem
Journal:  Histochem J       Date:  1995-09

10.  Stemness in human thyroid cancers and derived cell lines: the role of asymmetrically dividing cancer stem cells resistant to chemotherapy.

Authors:  Risheng Ma; Noga Minsky; Syed A Morshed; Terry F Davies
Journal:  J Clin Endocrinol Metab       Date:  2014-02-25       Impact factor: 5.958

View more
  2 in total

1.  Immunohistochemical Analysis of Cancer Stem Cell Marker Expression in Papillary Thyroid Cancer.

Authors:  Hye Min Kim; Ja Seung Koo
Journal:  Front Endocrinol (Lausanne)       Date:  2019-08-02       Impact factor: 5.555

2.  Asymptomatic neurotoxicity of amyloid β-peptides (Aβ1-42 and Aβ25-35) on mouse embryonic stem cell-derived neural cells.

Authors:  Nur Izzati Mansor; Carolindah Makena Ntimi; Noraishah Mydin Abdul-Aziz; King-Hwa Ling; Aishah Adam; Rozita Rosli; Zurina Hassan; Norshariza Nordin
Journal:  Bosn J Basic Med Sci       Date:  2021-02-01       Impact factor: 3.363

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.